Significant corporate developments are in focus today.

Anker Innovations Technology Co.,Ltd. (HKEX: 300866) has initiated its initial public offering subscription period, running from June 23rd to June 26th, and has secured cornerstone investors including Taikang Life Insurance.

DELTON (HKEX: 01989) has announced plans to invest in the construction of the Dongguan Intelligent Manufacturing Headquarters project in Machong Town, with an expected total investment of 6 billion yuan.

Insilico Medicine (HKEX: 03696) has entered into a potential $2.5 billion AI-driven R&D collaboration with SK Biopharmaceuticals in the field of neuroimmune diseases.

Innovusion (HKEX: 02665) has been added to the FTSE Global Equity Index Series.

Hansi Bio-Tech (HKEX: 03378) has been included in the FTSE Global Micro Cap Index.

ZTO Express Inc. (HKEX: ZTO) has acquired the remaining equity interest in TuXi Tech for 1.305 billion yuan.

Hengrui Medicine (HKEX: 01276) has announced that the Marketing Authorization Application for its drug Rezvilutamide tablets has been accepted by the European Medicines Agency (EMA).

Estun Automation (HKEX: 02715) intends to absorb and merge its wholly-owned subsidiary, Nanjing Estun Automatic Control Technology.

Financial Performance Updates

Duk Sun Holdings (HKEX: 00199) reported a significant reduction in losses for the 2026 fiscal year, marked by notable financial improvement and new growth avenues from its AI infrastructure investments.

GBM (HKEX: 02161) released its annual results, showing a profit attributable to equity holders of approximately 201 million Hong Kong dollars, representing an increase of about 1.9% year-on-year.